微卡注射液联合左氧氟沙星治疗耐多药肺结核临床观察(1)
 |
| 第1页 |
参见附件(1914KB，2页)。
[摘要] 目的：探讨左氧氟沙星联合微卡注射液治疗耐多药肺结核的临床效果。方法：选择我院2009年12月～2010年12月耐多药肺结核患者81例，将以上患者随机分为观察组和对照组。对照组患者应用6AM..Pa.Z.Clr(E)/18.Pa.Z. Clr(E)化疗，观察组在对照化疗的基础上给予微卡注射液和左氧氟沙星。两组患者观察期为6个月。结果：观察组临床症状改善率、细菌转阴率、X线疗效总有效率、空洞愈合率显著高于对照组，差异有统计学意义(P<0.05)。结论：微卡注射液联合左氧氟沙星能够显著改善耐多药肺结核患者临床症状，临床效果显著。
[关键词] 肺结核；耐药；微卡注射液；左氧氟沙星
[中图分类号] R521[文献标识码]B [文章编号]1673-7210(2011)04(a)-078-02
Clinical observation of microcalorie chems injection combined with Levofloxacin on multi-drug resistant pulmonary tuberculosis
GUO Wei
The Second People′s Hospital of Zhongshan City, Guangdong Province, Zhongshan 528400, China
[Abstract] Objective: To explore the clinical efficacy of microcalorie chems injection combined with Levofloxacin on multi-drug resistant pulmonary tuberculosis. Methods: 81 cases with multi-drug resistant pulmonary tuberculosis were selected from December 2009 to December 2010 and randomly divided into observation group and control group. The chemotherapy regimen of 6AM..Pa.Z.Clr(E)/18.Pa.Z. Clr(E)was used to control group. microcalorie chems combined with Levofloxacin was given to observation group on the base of control group, the course was six months in two groups. Results: The symptoms improvement rate, bacterial negative rate, the efficacy rate of X- ray and cavity healing rate in observation group compared with those in control goup，there all were statistical difference (all P<0.05). Conclusion: Microcalorie chems combined with Levofloxacin can improve the symptoms of the patients with multi-drug resistant pulmonary tuberculosis，the clinical efficacy is significant.
[Key words] Pulmonary tuberculosis; Drug resistant; Microcalorie chems; Levofloxacin
近些年来，肺结核发病情况有增高趋势，而耐多药肺结核患者也逐渐增多。由于耐多药肺结核不容易治愈，严重影响了患者生命健康和生存治疗。本文探讨微卡注射液联合左氧氟沙星治疗耐多药肺结核临床治疗效果，现报道如下：
1 资料与方法
1.1一般资料
选择我院2009年12月～2010年12月耐多药肺结核患者81例，以上患者均有不同程度的咳嗽、咳痰、咯血、低热、乏力、盗汗等症状，均经过痰结核培养证实为阳性，均经过正规化疗，药敏试验显示对两种或者两种以上药物耐药。同时排除孕妇、哺乳期妇女、吸毒患者，排除近3个月内没有应用对免疫有影响的药物；排除肝肾功能障碍患者。所选患者均对本试验知情同意。将以上患者随机分为两组，观察组和对照组。其中观察组41例，男21例，女20例；年龄20～62岁，平均(34.3±6.8)岁；病程2.1～18年，平均(6.8±2 ......
您现在查看是摘要介绍页，详见PDF附件(1914KB，2页)。